McKesson to Acquire Precision Medicine Group for $2.25 Billion
核心洞察
McKesson Corporation signed a definitive agreement to acquire Precision Medicine Group (搜索), a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.
Following completion, Precision Medicine Group (搜索) will report within McKesson's Oncology & Multispecialty segment, enhancing clinical trial execution and broadening clinical service offerings.
The acquisition strengthens McKesson's oncology and multispecialty strategy by adding biomarker intelligence, lab services, a global CRO, and market access consulting capabilities.
McKesson Corporation has signed a definitive agreement to acquire Precision Medicine Group (搜索), LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion. The transaction marks another step in McKesson's effort to deepen its oncology and multispecialty footprint while strengthening its clinical research and commercialization capabilities.
Following completion of the transaction, Precision Medicine Group (搜索) will report within McKesson's Oncology & Multispecialty segment. Precision Medicine Group supports next-generation approaches to drug development and commercialization, providing biotechnology and pharmaceutical companies with integrated services and technology-enabled products that span biomarker intelligence, lab services, a global clinical research organization, market access consulting, and commercialization support.
"This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy and reflects our continued commitment to providing patients with access to the highest quality of care," said Brian Tyler, chair and chief executive officer of McKesson. "Precision Medicine Group (搜索) brings complementary capabilities that will enhance our clinical research and commercialization services, strengthen clinical trial execution, and broaden our clinical service offerings."
Margaret Keegan, chief executive officer of Precision Medicine Group (搜索), described the combination as a compelling opportunity. "Joining McKesson provides a compelling opportunity to extend the impact of our clinical and commercial expertise for the benefit of our customers, partners and patients they serve," Keegan said. "Together, we will bring a broader set of capabilities to biopharma companies, supporting them through the development and commercialization process. We are excited to join McKesson and advance our shared commitment to enabling innovation and improving patient access."
The acquisition underscores how consolidation is reshaping the movement of drugs from clinical development into commercial reach. McKesson, a healthcare company that provides pharmaceutical distribution and healthcare information, stated that the acquisition would enhance its clinical research and commercialization services, strengthen clinical trial execution, and broaden its clinical service offerings.
In pre-market trading, MCK was trading at $871.38, down 0.26% on the NYSE.
The deal arrives alongside a parallel industry shift toward artificial intelligence in commercialization. In a separate development, Lundbeck entered a strategic partnership with Eversana (搜索) to advance AI-powered commercialization across its U.S. commercial organization. That collaboration broadens Lundbeck's use of Eversana's AI Agency platform, creating a scalable framework for accelerating strategy development, content creation, omnichannel engagement, and commercial execution.
Launched in 2025 and developed in collaboration with Google Cloud (搜索), Eversana (搜索)'s AI Agency is an end-to-end AI-powered commercialization platform built specifically for life sciences, combining agentic AI, advanced automation, and human expertise while supporting the compliance and governance requirements unique to the pharmaceutical industry.
"The future of commercialization will belong to organizations that successfully combine human expertise with AI-driven execution," said Mark Thierer, chief executive officer of Eversana (搜索). "Lundbeck is advancing innovation and actively implementing new ways of working. Together, we are creating a model that pairs the power of artificial intelligence with deep life sciences expertise to help commercial teams move faster, operate more efficiently and deliver greater impact."
Together, these developments illustrate how scale and technology are converging to reshape pharmaceutical commercialization, with McKesson betting on expanded clinical and commercial capabilities and Lundbeck betting on AI-driven execution.